-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of CDE showed that the listing application of Qihuang Mingmu capsule submitted by Yiling Pharmaceutical in the new drug class 1.
1 was accepted
.
As one of the leading innovative enterprises of traditional Chinese medicine in China, Yiling Pharmaceutical holds 13 patented new drugs, and the total sales of 3 exclusive proprietary Chinese medicines in 6 major markets in China's three terminals will be close to 10 billion yuan in 2021; R&D investment has risen, the results have gradually been cashed in, and since 2020, 3 new Chinese medicine drugs have been approved, leading other Chinese medicine enterprises
in China.
In addition, 6 innovative Chinese medicines (1 reporting, 3 in Phase III clinical) and 4 chemical drugs and 1 new drugs (1 soon to be reported) are on the way
.
1 was accepted
.
As one of the leading innovative enterprises of traditional Chinese medicine in China, Yiling Pharmaceutical holds 13 patented new drugs, and the total sales of 3 exclusive proprietary Chinese medicines in 6 major markets in China's three terminals will be close to 10 billion yuan in 2021; R&D investment has risen, the results have gradually been cashed in, and since 2020, 3 new Chinese medicine drugs have been approved, leading other Chinese medicine enterprises
in China.
In addition, 6 innovative Chinese medicines (1 reporting, 3 in Phase III clinical) and 4 chemical drugs and 1 new drugs (1 soon to be reported) are on the way
.
With 13 patented new drugs in hand, 3 exclusive proprietary Chinese medicines sold for 10 billion
Relying on the self-contained "theory of network disease" Traditional Chinese medicine theory, Yiling Pharmaceutical has been approved 13 patented new drugs, including macaroni capsules/tablets, Ginsengsong Yangxin capsules, alfalfa qiangxin capsules, Lianhua Qingyi capsules/granules/tablets, Jinlida granules, Yangzheng anti-accumulation capsules, Xia Liqi capsules, Lianhua qing cough tablets, anti-depression and anti-annoyance capsules, kidney and heart-nourishing tablets, etc.
, and is in the leading position
in the field of medicines in the cardiovascular system, cold proprietary Chinese medicines, diabetes chinese patent medicines and other drugs.
, and is in the leading position
in the field of medicines in the cardiovascular system, cold proprietary Chinese medicines, diabetes chinese patent medicines and other drugs.
Lianhua Qingpeng capsules/granules are the core products of Ling Pharmaceutical, which are the national medical insurance Class A and national basic drugs, and have been recommended
by multiple diagnosis and treatment programs for many consecutive times.
According to data from the intranet, in 2020, the sales of Lianhua Qingpeng in China's three major terminal and 6 major markets (the statistical scope is detailed at the end of this article) exceeded 4 billion yuan for the first time, and in 2021, it will still achieve nearly 15% growth
on the basis of high base.
by multiple diagnosis and treatment programs for many consecutive times.
According to data from the intranet, in 2020, the sales of Lianhua Qingpeng in China's three major terminal and 6 major markets (the statistical scope is detailed at the end of this article) exceeded 4 billion yuan for the first time, and in 2021, it will still achieve nearly 15% growth
on the basis of high base.
In 2021, among the top 10 generic names of terminal cold proprietary Chinese medicines in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions), Lianhua Qingyi dominated
with a market share of 41.
78%.
with a market share of 41.
78%.
In recent years, China's three major terminals and 6 major markets lianhua qing plague sales (: 10,000 yuan)
Source: Intranet Database
Tongxinluo Capsules, Ginsengsong Yangxin Capsules, and Qiqi Qiangxin Capsules are the three major fist products of Ling Pharmaceutical in the field of cardiovascular chinese patent medicine, and they are all exclusive, national medical insurance Class A, national basic drug species, and the "main battlefield" is in the hospital market (public hospital + public primary medical care).
In 2021, among the top 20 final cardiovascular proprietary Chinese medicine products of Public Medical Institutions in China, the above three major products ranked 3rd, 5th and 18th respectively
.
In 2021, among the top 20 final cardiovascular proprietary Chinese medicine products of Public Medical Institutions in China, the above three major products ranked 3rd, 5th and 18th respectively
.
Tongxin capsule has the effect of invigorating blood and relieving pain, and is used for coronary heart disease, angina is a lack of heart qi, and blood stasis obstruction
.
In 2021, the total sales scale of the product in China's three major terminal and six major markets will be close to 2.
9 billion yuan, an increase of 12.
3%
year-on-year.
.
In 2021, the total sales scale of the product in China's three major terminal and six major markets will be close to 2.
9 billion yuan, an increase of 12.
3%
year-on-year.
In recent years, the sales of macaroni network in China's three major terminal markets (: 10,000 yuan)
Source: Intranet Database
GinsengSong Yangxin Capsule has the effect of nourishing qi and nourishing yin, invigorating blood circulation, purifying the heart and calming the nerves, and is used to treat coronary heart disease
caused by qi and yin deficiency and heart network stasis.
In 2021, the total sales scale of the product in China's three major terminal and six major markets exceeded 2 billion yuan for the first time, an increase of nearly 20%
year-on-year.
caused by qi and yin deficiency and heart network stasis.
In 2021, the total sales scale of the product in China's three major terminal and six major markets exceeded 2 billion yuan for the first time, an increase of nearly 20%
year-on-year.
In recent years, China's three major terminals and 6 major markets ginseng pine heart sales (: 10,000 yuan)
Source: Intranet Database
Amaranth Heart Strengthening Capsule has the effect of improving temperature and yang, activating blood circulation, water and swelling, and is used for mild and moderate congestive heart failure caused by coronary heart disease and hypertension
.
In 2021, the total sales scale of the product in China's three major terminal and six major markets exceeded 900 million yuan, an increase of 48.
14%
year-on-year.
.
In 2021, the total sales scale of the product in China's three major terminal and six major markets exceeded 900 million yuan, an increase of 48.
14%
year-on-year.
In recent years, China's three major terminals and 6 major markets Alfalfa Qiangxin sales (: 10,000 yuan)
Source: Intranet Database
In the field of diabetes treatment, Jinlida granules are the exclusive varieties of Yiling Pharmaceutical, which is a national medical insurance class B and a national basic drug, which has the effect of nourishing yin and healthy spleen, and is used for type 2 diabetes qi and yin
.
The product will have sales of more than 150 million yuan in the terminal of public medical institutions in China in 2021, ranking second
in the ranking of diabetes proprietary Chinese medicine products with a market share of 10.
7%.
.
The product will have sales of more than 150 million yuan in the terminal of public medical institutions in China in 2021, ranking second
in the ranking of diabetes proprietary Chinese medicine products with a market share of 10.
7%.
Approved as a "bellwether", 6 innovative Chinese medicine drugs are on the way
As one of the leading enterprises in the innovation of traditional Chinese medicine, Yiling Pharmaceutical continues to increase its research and development efforts to conduct patented new drug research
and development in the fields of cardiovascular and cerebrovascular system diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary system diseases and other clinical and major diseases.
The performance report shows that in the first half of 2022, Ling Pharmaceutical invested 385 million yuan in research and development, accounting for 6.
9%
of revenue.
Among the A-share listed Chinese medicine enterprises, Ling Pharmaceutical ranked third
in terms of R&D investment.
and development in the fields of cardiovascular and cerebrovascular system diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary system diseases and other clinical and major diseases.
The performance report shows that in the first half of 2022, Ling Pharmaceutical invested 385 million yuan in research and development, accounting for 6.
9%
of revenue.
Among the A-share listed Chinese medicine enterprises, Ling Pharmaceutical ranked third
in terms of R&D investment.
2019H1-2022H1 R&D investment of Yiling Pharmaceutical (: 100 million yuan)
Source: Company Announcement
Since 2020, 16 new Chinese medicine drugs (in terms of drug name + enterprise, excluding APIs) have been approved for listing, covering anti-tumor, respiratory system, nervous system, gynecology, orthopedics and other therapeutic fields
.
Judging from the approval of enterprises, Yiling Pharmaceutical has a total of 3 new Chinese medicine drugs approved for listing, leading other Chinese medicine enterprises
.
.
Judging from the approval of enterprises, Yiling Pharmaceutical has a total of 3 new Chinese medicine drugs approved for listing, leading other Chinese medicine enterprises
.
New Chinese medicine drugs approved for marketing since 2020 (excluding APIs)
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
In terms of the research and development of innovative Chinese medicine drugs, the company currently has 6 new Chinese medicine drugs in the clinical and above stages of approval, of which Qihuang Mingmu Capsules have submitted a listing application for the treatment of diabetic retinopathy
.
.
Paralysis tablets (rheumatoid arthritis), chai huang choleretic capsules (chronic cholecystitis), and Yuping tong tablets (persistent allergic rhinitis) are undergoing phase III clinical trials
.
It is worth mentioning that although these three new Chinese medicine drugs are declared as new drugs in category 6, with the implementation of the new registration management measures, they will also submit listing applications
in the future with new drugs 1.
1.
.
It is worth mentioning that although these three new Chinese medicine drugs are declared as new drugs in category 6, with the implementation of the new registration management measures, they will also submit listing applications
in the future with new drugs 1.
1.
Yiling Pharmaceutical is researching new chinese medicine drugs
Source: Minnet China Drug Clinical Trial Publicity Library
In addition, Yiling Pharmaceutical is also actively and continuously carrying out post-market re-evaluation and secondary development of listed Chinese medicine varieties, among which Yangzheng Anti-accumulation Capsules are applying for new indications
.
.
13 varieties have been evaluated, and the first chemical drug class 1 new drug is about to be produced
While carrying out innovative Chinese medicine research and development, Yiling Pharmaceutical is also actively laying out chemical drugs, biological drugs and health industries, and building a pharmaceutical and health industry pattern
in which patented Chinese medicine, chemical and biological drugs, and health industries develop in synergy and promote each other.
in which patented Chinese medicine, chemical and biological drugs, and health industries develop in synergy and promote each other.
In terms of innovative chemical drugs, Yiling Pharmaceutical has 4 new class 1 drugs into the clinical stage, of which anilineprofen injection has made the fastest progress, which is a non-steroidal analgesic, which is intended to be used for postoperative pain, various cancer pain, low back pain, gout attacks, neuralgia, etc
.
Its postoperative moderate to severe pain indications have completed phase III clinical trials and are about to declare NDA
.
.
Its postoperative moderate to severe pain indications have completed phase III clinical trials and are about to declare NDA
.
Yiling Pharmaceutical is developing innovative drugs for chemical drugs
Source: Minnet China Drug Clinical Trial Publicity Library
In terms of chemical generic drugs, 13 varieties of Ling Pharmaceutical have passed or are regarded as consistency evaluations, focusing on systemic anti-infective drugs, digestive and metabolic drugs, cardiovascular and cerebrovascular system drugs and other fields, of which ciprofloxacin hydrochloride tablets are the first to be evaluated
.
.
To Ling Pharmaceutical Consistency Evaluation Declaration
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
In addition, 3 varieties submitted supplementary applications for consistency evaluation and are under review, and 6 varieties were produced in new classifications, of which sakuba valsartan sodium tablets were not approved for the first time, and the global sales of the original research products reached 3.
548 billion US dollars in 2021, while the sales in the 6 major markets of China's three terminals exceeded 2 billion yuan, an increase of 127.
6%
year-on-year.
548 billion US dollars in 2021, while the sales in the 6 major markets of China's three terminals exceeded 2 billion yuan, an increase of 127.
6%
year-on-year.
In the overseas market, Yiling Pharmaceutical has so far obtained FDA approval for 13 ADNA document numbers, of which paroxetine hydrochloride tablets, valacyclovir hydrochloride tablets, buspirone hydrochloride tablets, lisinopril tablets, lamotrizine extended-release tablets, acyclovir capsules and other varieties have not been reported to China
.
.
Source: Intranet database, listed company announcements, etc.
Note: Intranet "China's Public Medical Institutions Terminal Competition Pattern", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Statistics as of September 9, if there is any omission, welcome to correct!
Note: Intranet "China's Public Medical Institutions Terminal Competition Pattern", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Statistics as of September 9, if there is any omission, welcome to correct!
A few days ago, the official website of CDE showed that the listing application of Qihuang Mingmu capsule submitted by Yiling Pharmaceutical in the new drug class 1.
1 was accepted
.
As one of the leading innovative enterprises of traditional Chinese medicine in China, Yiling Pharmaceutical holds 13 patented new drugs, and the total sales of 3 exclusive proprietary Chinese medicines in 6 major markets in China's three terminals will be close to 10 billion yuan in 2021; R&D investment has risen, the results have gradually been cashed in, and since 2020, 3 new Chinese medicine drugs have been approved, leading other Chinese medicine enterprises
in China.
In addition, 6 innovative Chinese medicines (1 reporting, 3 in Phase III clinical) and 4 chemical drugs and 1 new drugs (1 soon to be reported) are on the way
.
1 was accepted
.
As one of the leading innovative enterprises of traditional Chinese medicine in China, Yiling Pharmaceutical holds 13 patented new drugs, and the total sales of 3 exclusive proprietary Chinese medicines in 6 major markets in China's three terminals will be close to 10 billion yuan in 2021; R&D investment has risen, the results have gradually been cashed in, and since 2020, 3 new Chinese medicine drugs have been approved, leading other Chinese medicine enterprises
in China.
In addition, 6 innovative Chinese medicines (1 reporting, 3 in Phase III clinical) and 4 chemical drugs and 1 new drugs (1 soon to be reported) are on the way
.
With 13 patented new drugs in hand, 3 exclusive proprietary Chinese medicines sold for <> billion
With 13 patented new drugs in hand, 3 exclusive proprietary Chinese medicines sold for 10 billion Relying on the self-contained "theory of network disease" Traditional Chinese medicine theory, Yiling Pharmaceutical has been approved 13 patented new drugs, including macaroni capsules/tablets, Ginsengsong Yangxin capsules, alfalfa qiangxin capsules, Lianhua Qingyi capsules/granules/tablets, Jinlida granules, Yangzheng anti-accumulation capsules, Xia Liqi capsules, Lianhua qing cough tablets, anti-depression and anti-annoyance capsules, kidney and heart-nourishing tablets, etc.
, and is in the leading position
in the field of medicines in the cardiovascular system, cold proprietary Chinese medicines, diabetes chinese patent medicines and other drugs.
, and is in the leading position
in the field of medicines in the cardiovascular system, cold proprietary Chinese medicines, diabetes chinese patent medicines and other drugs.
Lianhua Qingpeng capsules/granules are the core products of Ling Pharmaceutical, which are the national medical insurance Class A and national basic drugs, and have been recommended
by multiple diagnosis and treatment programs for many consecutive times.
According to data from the intranet, in 2020, the sales of Lianhua Qingpeng in China's three major terminal and 6 major markets (the statistical scope is detailed at the end of this article) exceeded 4 billion yuan for the first time, and in 2021, it will still achieve nearly 15% growth
on the basis of high base.
by multiple diagnosis and treatment programs for many consecutive times.
According to data from the intranet, in 2020, the sales of Lianhua Qingpeng in China's three major terminal and 6 major markets (the statistical scope is detailed at the end of this article) exceeded 4 billion yuan for the first time, and in 2021, it will still achieve nearly 15% growth
on the basis of high base.
In 2021, among the top 10 generic names of terminal cold proprietary Chinese medicines in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions), Lianhua Qingyi dominated
with a market share of 41.
78%.
with a market share of 41.
78%.
In recent years, China's three major terminals and 6 major markets lianhua qing plague sales (: 10,000 yuan)
Source: Intranet Database
Tongxinluo Capsules, Ginsengsong Yangxin Capsules, and Qiqi Qiangxin Capsules are the three major fist products of Ling Pharmaceutical in the field of cardiovascular chinese patent medicine, and they are all exclusive, national medical insurance Class A, national basic drug species, and the "main battlefield" is in the hospital market (public hospital + public primary medical care).
In 2021, among the top 20 final cardiovascular proprietary Chinese medicine products of Public Medical Institutions in China, the above three major products ranked 3rd, 5th and 18th respectively
.
In 2021, among the top 20 final cardiovascular proprietary Chinese medicine products of Public Medical Institutions in China, the above three major products ranked 3rd, 5th and 18th respectively
.
Tongxin capsule has the effect of invigorating blood and relieving pain, and is used for coronary heart disease, angina is a lack of heart qi, and blood stasis obstruction
.
In 2021, the total sales scale of the product in China's three major terminal and six major markets will be close to 2.
9 billion yuan, an increase of 12.
3%
year-on-year.
.
In 2021, the total sales scale of the product in China's three major terminal and six major markets will be close to 2.
9 billion yuan, an increase of 12.
3%
year-on-year.
In recent years, the sales of macaroni network in China's three major terminal markets (: 10,000 yuan)
Source: Intranet Database
GinsengSong Yangxin Capsule has the effect of nourishing qi and nourishing yin, invigorating blood circulation, purifying the heart and calming the nerves, and is used to treat coronary heart disease
caused by qi and yin deficiency and heart network stasis.
In 2021, the total sales scale of the product in China's three major terminal and six major markets exceeded 2 billion yuan for the first time, an increase of nearly 20%
year-on-year.
caused by qi and yin deficiency and heart network stasis.
In 2021, the total sales scale of the product in China's three major terminal and six major markets exceeded 2 billion yuan for the first time, an increase of nearly 20%
year-on-year.
In recent years, China's three major terminals and 6 major markets ginseng pine heart sales (: 10,000 yuan)
Source: Intranet Database
Amaranth Heart Strengthening Capsule has the effect of improving temperature and yang, activating blood circulation, water and swelling, and is used for mild and moderate congestive heart failure caused by coronary heart disease and hypertension
.
In 2021, the total sales scale of the product in China's three major terminal and six major markets exceeded 900 million yuan, an increase of 48.
14%
year-on-year.
.
In 2021, the total sales scale of the product in China's three major terminal and six major markets exceeded 900 million yuan, an increase of 48.
14%
year-on-year.
In recent years, China's three major terminals and 6 major markets Alfalfa Qiangxin sales (: 10,000 yuan)
Source: Intranet Database
In the field of diabetes treatment, Jinlida granules are the exclusive varieties of Yiling Pharmaceutical, which is a national medical insurance class B and a national basic drug, which has the effect of nourishing yin and healthy spleen, and is used for type 2 diabetes qi and yin
.
The product will have sales of more than 150 million yuan in the terminal of public medical institutions in China in 2021, ranking second
in the ranking of diabetes proprietary Chinese medicine products with a market share of 10.
7%.
.
The product will have sales of more than 150 million yuan in the terminal of public medical institutions in China in 2021, ranking second
in the ranking of diabetes proprietary Chinese medicine products with a market share of 10.
7%.
Approved as a "bellwether", 6 innovative Chinese medicine drugs are on the way
Approved as a "bellwether", 6 innovative Chinese medicine drugs are on the way As one of the leading enterprises in the innovation of traditional Chinese medicine, Yiling Pharmaceutical continues to increase its research and development efforts to conduct patented new drug research
and development in the fields of cardiovascular and cerebrovascular system diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary system diseases and other clinical and major diseases.
The performance report shows that in the first half of 2022, Ling Pharmaceutical invested 385 million yuan in research and development, accounting for 6.
9%
of revenue.
Among the A-share listed Chinese medicine enterprises, Ling Pharmaceutical ranked third
in terms of R&D investment.
Enterprise enterpriseand development in the fields of cardiovascular and cerebrovascular system diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary system diseases and other clinical and major diseases.
The performance report shows that in the first half of 2022, Ling Pharmaceutical invested 385 million yuan in research and development, accounting for 6.
9%
of revenue.
Among the A-share listed Chinese medicine enterprises, Ling Pharmaceutical ranked third
in terms of R&D investment.
2019H1-2022H1 R&D investment of Yiling Pharmaceutical (: <> million yuan)
Source: Company Announcement
Since 2020, 16 new Chinese medicine drugs (in terms of drug name + enterprise, excluding APIs) have been approved for listing, covering anti-tumor, respiratory system, nervous system, gynecology, orthopedics and other therapeutic fields
.
Judging from the approval of enterprises, Yiling Pharmaceutical has a total of 3 new Chinese medicine drugs approved for listing, leading other Chinese medicine enterprises
.
Pharmaceuticals.
Judging from the approval of enterprises, Yiling Pharmaceutical has a total of 3 new Chinese medicine drugs approved for listing, leading other Chinese medicine enterprises
.
New Chinese medicine drugs approved for marketing since 2020 (excluding APIs)
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
In terms of the research and development of innovative Chinese medicine drugs, the company currently has 6 new Chinese medicine drugs in the clinical and above stages of approval, of which Qihuang Mingmu Capsules have submitted a listing application for the treatment of diabetic retinopathy
.
.
Paralysis tablets (rheumatoid arthritis), chai huang choleretic capsules (chronic cholecystitis), and Yuping tong tablets (persistent allergic rhinitis) are undergoing phase III clinical trials
.
It is worth mentioning that although these three new Chinese medicine drugs are declared as new drugs in category 6, with the implementation of the new registration management measures, they will also submit listing applications
in the future with new drugs 1.
1.
.
It is worth mentioning that although these three new Chinese medicine drugs are declared as new drugs in category 6, with the implementation of the new registration management measures, they will also submit listing applications
in the future with new drugs 1.
1.
Yiling Pharmaceutical is researching new chinese medicine drugs
Source: Minnet China Drug Clinical Trial Publicity Library
In addition, Yiling Pharmaceutical is also actively and continuously carrying out post-market re-evaluation and secondary development of listed Chinese medicine varieties, among which Yangzheng Anti-accumulation Capsules are applying for new indications
.
.
13 varieties have been evaluated, and the first chemical drug class 1 new drug is about to be produced
13 varieties have been evaluated, and the first chemical drug class 1 new drug is about to be produced While carrying out innovative Chinese medicine research and development, Yiling Pharmaceutical is also actively laying out chemical drugs, biological drugs and health industries, and building a pharmaceutical and health industry pattern
in which patented Chinese medicine, chemical and biological drugs, and health industries develop in synergy and promote each other.
Health and health medicinein which patented Chinese medicine, chemical and biological drugs, and health industries develop in synergy and promote each other.
In terms of innovative chemical drugs, Yiling Pharmaceutical has 4 new class 1 drugs into the clinical stage, of which anilineprofen injection has made the fastest progress, which is a non-steroidal analgesic, which is intended to be used for postoperative pain, various cancer pain, low back pain, gout attacks, neuralgia, etc
.
Its postoperative moderate to severe pain indications have completed phase III clinical trials and are about to declare NDA
.
.
Its postoperative moderate to severe pain indications have completed phase III clinical trials and are about to declare NDA
.
Yiling Pharmaceutical is developing innovative drugs for chemical drugs
Source: Minnet China Drug Clinical Trial Publicity Library
In terms of chemical generic drugs, 13 varieties of Ling Pharmaceutical have passed or are regarded as consistency evaluations, focusing on systemic anti-infective drugs, digestive and metabolic drugs, cardiovascular and cerebrovascular system drugs and other fields, of which ciprofloxacin hydrochloride tablets are the first to be evaluated
.
.
To Ling Pharmaceutical Consistency Evaluation Declaration
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
In addition, 3 varieties submitted supplementary applications for consistency evaluation and are under review, and 6 varieties were produced in new classifications, of which sakuba valsartan sodium tablets were not approved for the first time, and the global sales of the original research products reached 3.
548 billion US dollars in 2021, while the sales in the 6 major markets of China's three terminals exceeded 2 billion yuan, an increase of 127.
6%
year-on-year.
548 billion US dollars in 2021, while the sales in the 6 major markets of China's three terminals exceeded 2 billion yuan, an increase of 127.
6%
year-on-year.
In the overseas market, Yiling Pharmaceutical has so far obtained FDA approval for 13 ADNA document numbers, of which paroxetine hydrochloride tablets, valacyclovir hydrochloride tablets, buspirone hydrochloride tablets, lisinopril tablets, lamotrizine extended-release tablets, acyclovir capsules and other varieties have not been reported to China
.
.
Source: Intranet database, listed company announcements, etc.
Note: Intranet "China's Public Medical Institutions Terminal Competition Pattern", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Statistics as of September 9, if there is any omission, welcome to correct!
Hospital Hospital Note: Intranet "China's Public Medical Institutions Terminal Competition Pattern", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Statistics as of September 9, if there is any omission, welcome to correct!
